MDxHealth
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 nov 2009 - 08:05
Statutaire naam
MDxHealth
Titel
OncoMethylome Announces Second Business Update for 2009 and Several Business Changes
Bericht
Liege (Belgium) – November 5, 2009, 8:00 AM CET – OncoMethylome Sciences announces today its third quarter financial results, the focusing of the business, an update on the status of certain of its products, and a change in management.
Q3 2009 material events
• Published new clinical data on the blood-based colorectal cancer screening test at Europe’s largest cancer congress (ECCO-ESMO)
• Published further clinical data on the urine-based bladder cancer detection test
• Remained on track for enrollment of new patients in the company’s largest clinical trials, such as the 7.000-patient colorectal cancer screening trial
Key non-audited financials, as of September 30th, 2009:
Amounts as at and for the three months ended
Euro thousands Sept. 30, 2009 Sept 30, 2008
Revenues 577 758
EBITDA Income (Loss) (2,797) (2,079)
EBIT Operating Income (Loss) (3,036) (2,330)
Net Profit (Loss) (2,907) (2,065)
Cash and cash equivalents 21,065 23,999
Amounts as at and for the nine months ended
Euro thousands Sept. 30, 2009 Sept 30, 2008
Revenues 1,845 2,279
EBITDA Income (Loss) (8,862) (7,800)
EBIT Operating Income (Loss) (9,565) (8,548)
Net Profit (Loss) (9,247) (7,765)
Cash and cash equivalents 21,065 23,999
Business changes and outlook after Q3 2009:
OncoMethylome announces a focusing of its diagnostics business on three clinical areas: colorectal, prostate and bladder cancer. Moreover, the geographical emphasis for market entry with its products will be on the USA, as it is and will be the main market for molecular diagnostics for the years to come. This implies that no direct sales and marketing force will be built up in Europe by OncoMethylome for the foreseeable future. OncoMethylome will continue to work closely with large distribution partners and leading national testing laboratories. Although the focusing will likely impact the current organization, it will allow OncoMethylome to expand clinical validation of the most advanced products in the key medical markets and
Datum laatste update: 03 september 2024